Enhancing Cancer Immunotherapy Via Activation of Innate Immunity.
Enhancing Cancer Immunotherapy Via Activation of Innate Immunity.
复制标题
DOI：
10.1053/j.seminoncol.2015.05.012
复制
发表时间：
2015-08
影响因子：
4
通讯作者：
Sondel PM
中科院分区：
文献类型：
--
作者：
Goldberg JL;Sondel PM
鉴于最近的技术进步和我们对癌症的理解的进步，癌症的免疫治疗正在以明显的临床益处被使用。伴随癌症本身的免疫抑制，以及目前用放射或化学疗法进行的癌症治疗，比先天效应细胞更大程度地损害适应性免疫效应细胞。除了较少受到抑制外，先天免疫细胞还能够通过免疫刺激方案得到增强。正在研究的促进针对癌症的先天免疫应答的大多数策略不需要复杂的、患者特异性的、离体细胞或分子的治疗剂产生;因此，它们通常可以用作可以由大多数癌症诊所施用的“现成”治疗剂。先天免疫疗法在临床中的成功应用已经有效地靶向先天免疫应答的组分。临床前数据表明先天免疫应答的启动如何导致随后的适应性长期癌症免疫。我们假设将先天免疫激活策略整合到癌症治疗的联合疗法中将导致更有效和长期的临床益处。
Given recent technological advances and advances in our understanding of cancer, immunotherapy of cancer is being used with clear clinical benefit. The immunosuppression accompanying cancer itself, as well as with current cancer treatment with radiation or chemotherapy, impairs adaptive immune effectors to a greater extent than innate effector cells. In addition to being less suppressed, innate immune cells are capable of being enhanced via immune-stimulatory regimens. Most strategies being investigated to promote innate immune responses against cancer do not require complex, patient-specific, ex-vivo cellular or molecular creation of therapeutic agents; thus they can, generally, be used as “off the shelf” therapeutics that could be administered by most cancer clinics. Successful applications of innate immunotherapy in the clinic have effectively targeted components of the innate immune response. Preclinical data demonstrate how initiation of innate immune responses can lead to subsequent adaptive long-term cancer immunity. We hypothesize that integration of innate immune activation strategies into combination therapies for cancer treatment will lead to more effective and long term clinical benefit.